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ABSTRACT Fosfomycin has become an attractive treatment alternative for urinary
tract infections (UTIs) due to increasing multidrug resistance (MDR) in Escherichia
coli. In this study, we evaluated the pharmacokinetic (PK) and pharmacodynamic
(PD) indices of fosfomycin and its in vivo activity in an experimental murine model
of ascending UTI. Subcutaneous administration of fosfomycin showed that the mean
peak plasma concentrations of fosfomycin were 36, 280, and 750 mg/liter following
administration of a single dose of 0.75, 7.5, and 30 mg/mouse, respectively, with an
elimination half-life of 28 min, and urine peak concentrations of 1,100, 33,400, and
70,000 mg/liter expected to be sustained above 1 mg/liter (MIC of the test strain,
NU14) for 5, 8, and 9.5 h, respectively. The optimal PK/PD indices for reducing urine
colony counts (number of CFU per milliliter) were determined to be the area under
the concentration-time curve/MIC from 0 to 72 h and the maximum concentration/
MIC on the basis of the dose-dependent bloodstream PK and the results of an eval-
uation of six dosing regimens. With a dosing regimen of 15 mg/mouse twice (every
36 h), fosfomycin significantly reduced the number of CFU per milliliter of all suscep-
tible strains in urine, including clinical MDR strains, except for one clinical strain (P 
0.062). Variable degrees of reduction were observed in the bladder and kidneys. No
significant reductions in the number of CFU per milliliter were observed with the re-
sistant strains. In conclusion, fosfomycin shows concentration-dependent in vivo ac-
tivity, and the results suggest that fosfomycin is an effective alternative to carbapen-
ems in treating MDR E. coli in uncomplicated UTIs. The data on the effectiveness of
fosfomycin against the MDR isolates along with the results of PK/PD modeling
should facilitate the further development of improved recommendations for its clini-
cal use.
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Urinary tract infections (UTIs) may progress to bloodstream infections (1), and theyaccount for 40% of hospital-acquired cases of sepsis (2, 3). Escherichia coli is
responsible for 75 to 90% cases of community-acquired UTIs (4–7). The increase in
antimicrobial resistance and multidrug resistance (MDR) among E. coli isolates (i.e.,
extended-spectrum--lactamase [ESBL]-producing E. coli isolates) is currently limiting
treatment options for UTIs (8). This could lead to the more extensive use of carbapen-
ems, which are reserved for use against other complicated infections (9). In addition,
carbapenemase-producing organisms are now spreading worldwide (10, 11). The lack
of effective antimicrobials due to the emergence of antimicrobial resistance inflates the
use of last-resort antimicrobials for common infections, such as UTIs. Alternative
therapeutic options for UTIs are therefore urgently needed (12).
As there are a very limited number of new antimicrobials in the pipeline, it has been
suggested that an alternative approach is to reevaluate the efficacy of old antimicro-
bials to extend the set of drugs available for the treatment of MDR infections (13–16).
One such agent is fosfomycin, a broad-spectrum bactericidal agent that has been
suggested to be an alternative treatment option for infections caused by MDR Gram-
negative bacteria (17). Fosfomycin acts on the cell wall by inactivating enolpyruvate
transferase, thereby blocking the condensation of UDP-N-acetylglucosamine with
p-enolpyruvate (18).
Recent studies have shown that fosfomycin exhibits potent in vitro activity against
both non-MDR and MDR Enterobacteriaceae, including ESBL- and carbapenemase-
producing isolates (18–20). However, increasing frequencies of fosfomycin resistance
have been observed in some countries where fosfomycin is used (18, 20). The emer-
gence of resistance during fosfomycin monotherapy occurs rapidly in vitro but is rarely
observed in vivo (21). Data on the pharmacokinetic (PK) and the pharmacodynamic (PD)
behavior of fosfomycin are somewhat conflicting among existing studies (22–26).
Docobo-Perez et al. (22) suggest insufficient evidence on efficacy to be among the
factors discouraging the use of fosfomycin as a treatment option. Therefore, reevalu-
ation of the in vivo activity and PK/PD properties of fosfomycin is required to develop
an effective dosing regimen that complies with current standards and that is applicable
to the current bacterial population (15, 16, 21). To our knowledge, no in vivo studies
have investigated the PK/PD of fosfomycin in UTIs during the past 2 decades.
Thus, the objectives of this study were to elucidate the predictive PK/PD index for
fosfomycin in an experimental model of ascending UTI, identify the dose that targets
appropriate exposure toward E. coli strains with decreased susceptibility to fosfomycin,
and investigate the in vivo activity of fosfomycin against MDR ESBL-, plasmid-mediated
AmpC-, and/or carbapenemase-producing E. coli in vivo.
RESULTS
Bacterial strain characteristics. The characteristics of the strains used in this study
are summarized in Table 1. On the basis of the results of whole-genome sequencing
(WGS) analysis, no resistance determinants were identified in the NU14 strain. The
sequence type (ST) of NU14 was determined to be ST1231. The MICs of fosfomycin for
NU14 and NU14-derived strains DA6313, DA6328, and DA6401 were determined to be
1, 2, 128, and 1,024 mg/liter, respectively.
Five of the clinical MDR E. coli isolates selected for the in vivo activity studies were
susceptible to fosfomycin with MICs of 0.5 to 2 mg/liter, while isolate P14-63 was
resistant with an MIC of 512 mg/liter. Two of the clinical isolates were carbapenemase
producers harboring blaNDM-1 (strain K71-77) or blaVIM-29 (strain 50639799). Three
isolates were ESBL producers harboring blaCTX-M-15, blaCTX-M-14, or blaCTX-M-3, while the
isolate with a plasmid-mediated AmpC harbored blaCMY-2. The fosfomycin-resistant
P14-63 isolate harbored the fosA gene. Multilocus sequence typing (MLST) analysis
showed that the isolates were diverse with respect to sequence types, with the
sequence types of the isolates including ST167, ST2016, ST420, ST410, ST6355, and
ST131.
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In vitro time-kill studies. In vitro time-kill studies with NU14 (Fig. 1) and the
susceptible clinical strains (Fig. 2A to E) at concentrations of 1 to 8 MIC showed an
initial rapid bactericidal effect up to 2 h, followed by regrowth at 24 h. At concentra-
tions of 16 to 32 MIC (64 MIC and higher for NU14), bacterial counts reached
levels below the limit of detection (LOD; 50 CFU/ml) at 2 to 4 h. No regrowth was
observed at 24 h for any of the susceptible strains, except for K5-08 and 50639799. For
NU14, MIC testing of the subsequently isolated colonies (at time points of 0 h, 4 h, and
24 h) showed 8- to 32-fold increases in the MIC at time points of 4 h and 24 h, whereas
there was no increase in the MIC for colonies from the control tube. The MICs for the
isolated colonies with an increased MIC remained stable after five passages on nonse-
lective Mueller-Hinton (MH) agar (data not shown).
For the resistant clinical strain P14-63 (Fig. 2F), transient killing was soon followed by
regrowth. After 24 h, regrowth was observed irrespective of the fosfomycin concen-
tration. For this strain, no dependence between the fosfomycin concentration and the
TABLE 1 Characteristics of the E. coli strains used in the study
Strain Specimen or origin
Fosfomycin MIC
(mg/liter) Resistance gene profile MLST type
NU14 Urine 1 ST1231
DA6313 NU14 derivative 2 ptsI deletion ST1231
DA6328 NU14 derivative 128 glpT missense mutation ST1231
DA6401 NU14 derivative 1,024 uhpT missense mutation ST1231
K4-40 Wound 2 aadA1, aac(6=)Ib-cr, blaCTX-M-15, blaOXA-1, blaTEM-1B, catB3, dfrA1,
erm(B), mph(A), strA, strB, sul2, tet(A)
ST167
K5-08 Urine 0.5 aadA5, blaCTX-M-14, dfrA17, sul2, tet(A) ST2016
K26-07 Urine 2 blaCMY-2 ST420
K71-77 Blood culture 2 aac(3)-IId, aac(6=)Ib-cr, aacA4, blaCMY-6, blaNDM-1, blaOXA-1,
catB3, rmtC, sul1
ST410
50639799 Urine 0.5 aac(3)-IIa, aac(6=)Ib-cr, aadA24, blaCMY-4, blaCTX-M-15, blaOXA-1,
blaVIM-29, catB3, dfrA1, floR, strA, strB, sul2, tet(A)
ST6355
P14-63 Urine 512 blaCTX-M-3, blaTEM-1B, fosA ST131
FIG 1 In vitro time-kill curves with fosfomycin against fosfomycin-susceptible E. coli NU14 (MIC, 1 mg/liter). The graph shows
the viable counts as the log10 number of CFU per milliliter at time points of 0 h, 30 min, 1 h, 2 h, 4 h, and 24 h. The horizontal
dotted line shows the limit of detection (LOD).
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rate of killing was found (i.e., lower concentrations could result in killing rates initially
higher than those achieved with higher concentrations of fosfomycin; in the case of 8
MIC and 32 MIC, the growth rates were close to the rates observed for the control).
The maximal bactericidal effect did not exceed 2 log10 CFU/ml of the initial number
of CFU per milliliter.
PK/PD of fosfomycin. (i) Pharmacokinetics. The plasma and urine concentrations
of fosfomycin were measured in mice after single subcutaneous (s.c.) doses of 0.75, 7.5,
and 30 mg/mouse. Peak fosfomycin plasma concentrations were 36, 280, and 750
mg/liter for the respective doses (Fig. 3A). The mean elimination half-life was 28 min.
In urine, peak fosfomycin concentrations of 33,400 and 70,000 mg/liter were reached
FIG 2 In vitro time-kill curves with fosfomycin against E. coli clinical isolates K4-40 (MIC, 2 mg/liter) (A), K5-08 (MIC, 0.5 mg/liter) (B), K26-07 (MIC, 2 mg/liter)
(C), K71-77 (MIC, 2 mg/liter) (D), 50639799 (MIC, 0.5 mg/liter) (E), and P14-63 (MIC, 512 mg/liter) (F). The graphs show viable counts as the log10 number of CFU
per milliliter at time points of 0 h, 30 min, 1 h, 2 h, 4 h, and 24 h. The horizontal dotted lines show the limit of detection (LOD).
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after 15 min with the 7.5- and 30-mg/liter doses, respectively (Fig. 3B). After 15 min, the
measured concentrations of fosfomycin for the 7.5- and 30-mg/liter doses were similar,
and the two doses followed the same elimination pattern. For the 0.75-mg dose, a peak
urine concentration of 1,100 mg/liter was reached after 30 min.
(ii) Dose fractionation and calculation of PK/PD indices. On the basis of the
results of the PK analysis, six dose regimens were designed (Table 2), in order to
produce variations in bloodstream PK/PD indices: 30 and 7.5 mg/mouse in a single
dose, 15 mg/mouse twice (every 36 h [q36h]), 1.88 and 0.47 mg/mouse every 6 h, and
0.47 mg/mouse every 12 h (q12h). Treatment was initiated at 24 h postinfection, and
the treatment period was 72 h for all doses used. PK/PD indices for the NU14 strain
were calculated using the systemic drug concentrations. The cumulative percentage of
a 72-h period that the drug concentration exceeded the MIC (percent TMIC) ranged
from 4 to 42%, the area under the concentration-time curve (AUC)/MIC ratios ranged
from 607 to 79 h1, and the maximum concentration (Cmax)/MIC (for doses of 30 mg
and 7.5 mg, the actual measured values were used to calculate Cmax/MIC) ratios ranged
from 750 to 22 (Table 2).
(iii) PK/PD analysis. The in vivo activity of the six dose regimens against the NU14
strain was further investigated to estimate the predictive value of the PK/PD indices for
FIG 3 Fosfomycin concentrations (in milligrams per liter) in plasma (A) and urine (B) in OF-1 mice
following subcutaneous administration of single doses of 30, 7.5, and 0.75 mg/mouse. The data are
presented as the mean for three mice at each time point. Error bars represent SDs.
TABLE 2 Fosfomycin dosing regimens, based on bloodstream PK data, applied in the















30 72 1 30 9 607 750
15 36 2 30 14 727 468
7.5 72 1 7.5 4 212 281
1.88 6 12 22.56 42 635 78
0.47 6 12 5.64 30 158 22
0.47 12 6 2.82 15 79 22
aTreatment was initiated at 24 h postinfection, and the treatment period was 72 h.
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a bactericidal effect. For all doses tested, the median number of CFU per milliliter in
urine and kidneys was reduced to below the LOD (50 CFU/ml) (Fig. 4A and C). However,
for some mice and on the basis of the dose, counts (number of CFU per milliliter) above
the LOD were observed in the urine of a fraction of the mice in each separate
experiment, with the fractions ranging from 0% (for a single dose of 30 mg/mouse and
two doses of 15 mg/mouse [q36h]) to 55.6% (for a dose of 0.47 mg/mouse twice a day
[q12h]) of the mice (Fig. 4A). This was also observed for the counts (number of CFU per
milliliter) in the kidneys, in which the fraction of mice with counts (number of CFU per
milliliter) above the LOD ranged from 16.6% (for doses of 7.5 and 30 mg/mouse) to
38.8% (for a dose of 0.47 mg/mouse q12h) (Fig. 4C). In the bladders, none of the median
counts (number of CFU per milliliter) fell below the LOD, but a reduction in median
counts (number of CFU per milliliter) of up to 2 log10 compared to the counts for the
control was observed for all doses tested (Fig. 4B).
For all infection sites, the PD indices with the best correlation with in vivo activity
were the AUC/MIC from 0 to 72 h (AUC/MIC0 –72) and Cmax/MIC (Fig. 5). The percent
TMIC for 72 h had minimal, if any, influence on the in vivo activity (R2  0.74, 0.36, and
0.7 for urine, bladder, and kidneys, respectively). However, the amount of time that the
concentration exceeded the MIC (TMIC in hours) for the first injection (which could also
serve as a surrogate for Cmax/MIC) also correlated well with the bactericidal effect. The
optimal AUC/MIC0 –72 ratio appeared to be 600 h1 for urine (R2  0.91) and 200
h1 for the bladder and kidneys (R2  0.91 and 0.97, respectively). The optimal values
of Cmax/MIC were 450 for urine (R2  0.88) and 280 for kidneys and bladder (R2 
0.91 and 0.98, respectively). On the basis of this finding, the treatment associated with
the best in vivo activity (15 mg of fosfomycin per mouse twice [q36h]) was selected for
further studies with clinical strains. This dose was calculated on the basis of a surface
area of a mouse to be 70 cm2, which correlates with a surface area of 17,200 cm2 in a
70-kg human. The calculation results in a human dose of 3.6 g, which is close to the
standard dose of 3 g fosfomycin used for treating UTIs in most clinical studies (27, 28).
In vivo activity studies. Both the NU14-derived isogenic and clinical MDR strains
were confirmed to be type 1 fimbria positive and virulent in the murine UTI model (data
not shown).
(i) NU14 and isogenic NU14-derived strains. Using the dose of 15 mg/mouse
twice (q36h), a reduction in the median number of CFU per milliliter was observed only
with fosfomycin-susceptible strain NU14 in urine (5.3-log reduction, P  0.0001),
bladder (4.9-log reduction, P  0.0006), and kidneys (2.13-log reduction, P  0.063) and
with fosfomycin-susceptible strain DA6313 in urine (5.8-log reduction, P  0.1326) (Fig.
6A) and bladder (1.7-log reduction, P  0.014) (Fig. 6B). No reduction was observed in
kidneys (Fig. 6C). For fosfomycin-resistant strains DA6328 and DA6401, no significant
reduction in the median counts (number of CFU per milliliter) was observed at any
infection site, except that a significant reduction in the number of CFU per milliliter was
observed in the kidneys for DA6328 (1.16 log reduction, P  0.041) (Fig. 6C).
(ii) Clinical MDR strains. The applied treatment regimen significantly reduced the
counts (number of CFU per milliliter) in urine compared to those achieved with the
vehicle for all fosfomycin-susceptible MDR clinical E. coli strains except one (strain
K71-77; P  0.062) (Fig. 7A). In the bladder and kidneys, the counts (number of CFU per
milliliter) were significantly reduced for 3/5 and 1/5 of the fosfomycin-susceptible
strains, respectively (Fig. 7B and C). No significant difference in the counts (number of
CFU per milliliter) between the treated and the vehicle groups was observed for the
fosfomycin-resistant strain (P14-63) at all infection sites (Fig. 7A to C).
Posttreatment studies. No significant changes in the MIC of fosfomycin for colo-
nies of selected isolates on day 2 and day 5 (n  71) from any infection site of either
the treatment or the vehicle group randomly picked from nonselective agar were
observed. All strains retained their expected determinants of resistance to third-
generation cephalosporins and/or carbapenems.
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FIG 4 Study of the effect of treatment with six fosfomycin dosing regimens (milligrams per mouse) against E.
coli NU14 (MIC, 1 mg/liter). The bacterial counts (number of CFU per milliliter) from urine (A), homogenized urine
bladder (B), and homogenized kidneys (C) in mice with UTIs at day 5 after the inoculation are shown. Each point
indicates the number of CFU per milliliter in a single animal. Solid horizontal lines represent the median bacterial
count for each group, and horizontal dotted lines represent the LOD.
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Pharmacokinetics/pharmacodynamics. Our first objective was to perform PK/PD
studies to find the predictive index for fosfomycin. In the mouse model, fosfomycin was
rapidly absorbed after s.c. injection. After an almost negligible distribution phase, the
drug was eliminated with a mean half-life of 28 min in plasma (Fig. 3). The elimination
rate in mice was almost 10 times faster than that observed in humans, as is usually seen
for drug kinetics in mice. No accumulation of the drug in serum is expected for the
observed concentrations due to its short half-life in mice. Due to a significant variation
in urinary drug concentrations and because it was not possible to measure the total
mass of excreted drug, we did not use these data in the PK/PD analysis. Interestingly,
the urine concentration curves of fosfomycin were similar for two different doses (30
mg and 7.5 mg), except at the time point of 15 min, where an approximately 4-fold
difference in peak urine concentrations was observed (Fig. 3B). This could suggest
saturable elimination in combination with first-order elimination. Other studies, in both
humans and animal models, suggest that fosfomycin is eliminated in kidneys exclu-
sively by glomerular filtration and is neither protein bound nor metabolized (29–35).
However, there are some examples of similar findings in human studies, where a ceiling
effect on excretion has been observed (36, 37). We believe that this phenomenon
deserves further studies, especially with respect to the optimal dosing regimen in
humans.
According to the results of time-kill studies, the bactericidal effect of fosfomycin was
rapid (2 h) and concentration dependent (Fig. 1 and 2). Regrowth after 24 h was also
shown to be concentration dependent and was observed for all the concentrations
below 16 to 32 MIC. Moreover, the MICs for the survivors increased 8- to 32-fold and
were stable, indicating the development of resistance. This is in contrast to the lack of
an increase in the MIC for randomly selected colonies posttreatment in vivo. Although
no firm conclusions can be drawn with respect to the in vivo emergence of fosfomycin
resistance in our experimental setup, the findings of the present study support previous
findings indicating differences between the in vitro and in vivo emergence of fosfomy-
cin resistance (38).
FIG 5 Relationship between AUC/MIC0 –72, percent TMIC (percent per 72 h), Cmax/MIC, and TMIC (in hours) after a single dose, based on plasma drug
concentrations (protein binding is assumed to be 0%) and fosfomycin efficacy against E. coli NU14 in the experimental UTI model. The dosing regimens applied
for the efficacy study are listed in Table 2. Six to 18 mice were used for the investigation of each dose. R2 represents the goodness of fit, as calculated in
GraphPad Prism software.
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We used bloodstream drug concentrations in the PK/PD analysis. According to
Frimodt-Møller (39), the serum PK/PD indices represent a more accurate predictor of
drug levels and treatment activity in kidneys. For activity in bladder, a combination of
urinary (lumen) and serum (bladder tissue) PK could be important. Our dosing regimens
FIG 6 Bacterial counts (number of CFU per milliliter) from urine (A), homogenized urine bladder (B), and homogenized
kidneys (C) of OF-1 mice treated for 3 days at 15 mg/mouse twice (q36h) or saline (control) after infection with isogenic
E. coli strains with decreasing susceptibility to fosfomycin. Solid horizontal lines represent the median bacterial count for
each group, and horizontal dotted lines represent the LOD.
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allowed variations in the magnitudes of the PK/PD indices. However, due to a high renal
clearance in mice, the TMIC did not exceed 42% for the strain used in the study. We
observed overall good activity for all dosing regimens, despite the relatively low
percent TMIC for some doses (Fig. 4). Due to the differences in pharmacokinetics
between mice and humans, we could not mimic all the parameters with one dose,
especially when the fact that we were assessing both plasma and urine concentrations
FIG 7 Bacterial counts (number of CFU per milliliter) from urine (A), homogenized urine bladder (B), and
homogenized kidneys (C) of OF-1 mice treated for 3 days at 15 mg/mouse twice (q36h) or saline (control) after
infection with virulent clinical E. coli isolates with various degrees of fosfomycin susceptibility. Solid horizontal lines
represent the median bacterial count for each group, and horizontal dotted lines represent the LOD.
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is taken into account. Mazzei et al. have reported that high fosfomycin urine concen-
trations (1,000 to 4,000 mg/liter) are achieved and remain at 100 mg/liter for at least 30
to 48 h (40), which is the pharmacokinetic basis for the oral 3-g single-dose regimen.
In our dose fractionation study, we used a set of doses which appeared to be related
to the standard human oral 3-g dose in different ways. In comparison with the PK of the
standard human oral 3-g dose, a dose of 0.47 mg/mouse had a comparable plasma
Cmax of 22 mg/liter (41), a dose of 7.5 mg/mouse had a comparable plasma AUC of 212
h1 (41), doses of 1.88 to 0.47 mg/mouse had comparable peaks in urine concentra-
tions (40) (however, the concentrations declined faster), and doses of 15 to 30 mg/liter
allowed the urine concentrations of fosfomycin to be retained at 100 mg/liter for the
longest time compared to the other doses used in this study, while plasma Cmax levels
were comparable to those obtained with intravenous (i.v.) bolus doses in humans (42).
The differences in PK parameters at different sites and for different doses can also be
seen to be an advantage, as it would allow us to isolate the PK/PD parameters which
are important for the successful treatment of UTIs with fosfomycin.
We used a proportion of the bactericidal effect approach, which allowed us to
account for both noninfected/self-recovered kidneys and the good overall activity seen
for all doses (Fig. 4). For urine and kidneys, the bactericidal effect was defined as the
number of CFU per milliliter below the LOD, while for the bladder, the bactericidal
effect was defined as the number of CFU per milliliter below the minimum count
observed in the control group. Similar results for the number of CFU per milliliter in the
bladder were previously observed in the same animal model with other antimicrobials
(43). For all infection sites, the optimal PK/PD indices were AUC/MIC0 –72 and Cmax/MIC.
Published data regarding the appropriate PK/PD index for fosfomycin are somewhat
inconsistent. Some authors (23, 24) consider TMIC to be an appropriate index; however
we, along with others (22, 26), found the AUC/MIC and/or Cmax/MIC to be more
appropriate. This may be because for most of the strains, the dose allowed the
fosfomycin concentrations to remain above the MIC for a substantial amount of time.
Treatment failures may happen due to the emergence of an inherently resistant
subpopulation. VanScoy et al. (25) showed in vitro that the time above the inherent
resistance inhibitory concentration (32 to 64 MIC, in their case) appeared to be the
optimal PK/PD index; our results do not contradict this hypothesis.
In vivo activity studies. In order to balance comparable serum concentrations and
prolonged fosfomycin concentrations in urine, a dose of 15 mg/mouse administered
twice (q36h) was considered to be the most effective and, in terms of surface area and
as discussed above, comparable to the standard human dose of 3 g fosfomycin used for
the treatment of UTIs. This dose is also expected to sustain fosfomycin concentrations
in urine of 100 mg/liter for the longest possible time (10 h) and was further used
for the treatment studies. The decrease in bactericidal effect was relative to the MICs for
the strains. For the isogenic strain NU14 derivative (DA6328) with an MIC of 128
mg/liter, the dose resulted in a reduction in the number of CFU per milliliter in urine for
some mice (3/6), which was, overall, statistically nonsignificant. For the same strain, no
reduction in the number of CFU per milliliter in the kidneys and bladder was observed
(Fig. 6).
The second objective of the study was to evaluate the activity of fosfomycin against
MDR E. coli in vivo. Fosfomycin significantly reduced the number of CFU per milliliter in
the urine and bladder for most of the isolates. Although not all the isolates showed
statistically significant reductions in the number of CFU per milliliter in the bladder and
kidneys, nonsignificant tendencies toward reductions could still be observed (Fig. 7).
For cases with low statistical significance, the results could be explained by the lower
total number of CFU per milliliter per organ compared to that in urine, and thus, the
difference in the reduction (between the treatment and vehicle-treated groups) was
smaller. The high proportion of low counts (number of CFU per milliliter) of some
strains in the kidneys in the vehicle-treated group (which could be interpreted as
indicating either that the animals were not infected or self-recovered) is considered a
PK/PD of Fosfomycin against MDR E. coli Causing UTI Antimicrobial Agents and Chemotherapy
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limitation of the model. We believe that this situation causes a lower level of statistical
significance when the two-tailed Mann-Whitney test for the counts (number of CFU per
milliliter) in kidneys is used. These results are in concordance with those of other studies
(43, 44) implementing the same animal model but using different antimicrobials and,
thus, can be considered to be due to the limitations of the model and not the action
of fosfomycin itself. The results indicate that fosfomycin might have a potential for use
in the treatment of upper UTIs (for strains with lower MICs and likely by use of a dose
or route of administration different from the standard 3 g oral single dose used in the
clinical setting), but this requires further studies.
The colony counts of the resistant clinical isolate harboring fosA (P14-63) were not
significantly reduced in vivo in this study, despite the high plasma and urinary con-
centrations (Fig. 7). In accordance with this finding, the time-kill studies also showed
that the strain was not inhibited even by concentrations exceeding 32 MIC (16,384
mg/liter). The same time-kill pattern for isolates with plasmid-mediated fosfomycin
resistance has also been previously observed (45). Examples of colinked fosA and ESBL
determinants have already been reported (46, 47). However, ad interim, the global rates
of susceptibility to fosfomycin remain high, including for ESBL- and carbapenemase-
producing Enterobacteriaceae (48, 49).
In conclusion, our observations support the notion that fosfomycin is a promising
option for the treatment of uncomplicated UTIs caused by MDR E. coli. The proportions
of susceptible isolates among the subgroup of ESBL or carbapenemase producers
remain high globally (19, 48, 49). The optimal PK/PD indices included AUC/MIC and
Cmax/MIC. The dose of 15 mg/mouse twice (q36h) demonstrated a good effect against
clinical isolates. To our knowledge, this is the first in vivo study reporting the successful
treatment of UTIs caused by carbapenemase-producing E. coli with fosfomycin.
MATERIALS AND METHODS
Bacterial strains and chemicals. The fosfomycin-susceptible clinical uropathogenic E. coli strain
(UPEC) NU14 (38) was used to evaluate the effect of different doses of fosfomycin for the PK/PD study.
The strain has been used in a number of studies of UPEC (50) as well as in the UTI model (51).
Three isogenic E. coli strains with decreasing fosfomycin susceptibility, DA6313, DA6328, and DA6401,
derived from NU14 (38), were included for evaluation of the selected doses in the UTI model. These
strains have increased MICs against fosfomycin due to chromosomal mutations/deletions (38), including
a deletion in ptsI (DA6313), a glpT missense mutation (DA6328), and a missense mutation in uhpT
(DA6401). Further, one fosfomycin-resistant and five fosfomycin-susceptible clinical ESBL-, plasmid-
mediated AmpC-, and/or carbapenemase-producing E. coli isolates were used to further evaluate the
efficacy of the selected doses. All isolates used in the study are listed in Table 1.
The MIC of fosfomycin was determined by agar dilution using Mueller-Hinton (MH) agar (Oxoid,
Waltham, MA) with the addition of 25 mg/liter glucose-6-phosphate (G6P; Sigma-Aldrich, St. Lois, MO),
as recommended by EUCAST (52) and by CLSI guidelines (53). Fosfomycin powder (fosfomycin disodium;
batch no. 20120323) was supplied by Ningbo Honor Chemtech Co., Ltd., Ningbo, China. Fosfomycin
disodium solution has been reported to be stable for both a short period (24 h) and longer periods of
up to 14 days (54, 55) and to have a long shelf-life (2.9  107 h) when stored in dry powder form (56).
Moreover, the potency of the powder was regularly reevaluated during the study by agar dilution MIC
testing of both a fresh solution and a solution that had been stored overnight at 4°C, and it remained
stable. A stock solution was prepared from dry powder prior to each experiment. E. coli ATCC 25922
(American Type Culture Collection, Manassas, VA) was used as a quality control organism in the
susceptibility testing and for the bioassay evaluating fosfomycin concentrations in the PK studies.
For the isolates used in the treatment study, the multilocus sequence type and resistance determi-
nants were explored by whole-genome sequencing (Illumina, San Diego, CA) and analysis of the
sequence at the Centre for Genomic Epidemiology (https://cge.cbs.dtu.dk/services/CGEpipeline-1.1).
Type 1 fimbria production, essential for establishment of a successful murine UTI (44), was confirmed
for all clinical MDR strains using a mannose-sensitive agglutination of yeast cells (Saccharomyces
cerevisiae, lot BAD0641-2; Idun Industri, Norway) as described before (57, 58).
In vitro time-kill studies. Time-kill studies were performed for all isolates as described previously
(59), with one minor modification. The bacterial suspension was added to tubes with fosfomycin instead
of addition of fosfomycin to the bacterial suspension. This reverse order was introduced to avoid possible
problems with fosfomycin solubility in the concentrated stock solution. The modification did not result
in a change of the final bacterial density or the fosfomycin concentration in the test tube. Comparison
of the time-kill curves obtained with the original protocol and the modified protocol did not show any
difference with the fosfomycin-sensitive isolates (data not shown). Briefly, colonies from an overnight
culture were suspended in 0.9% saline to an optical density at 546 nm of 0.13. One milliliter of the
bacterial suspension was added to a tube containing 9 ml MH broth (Mueller-Hinton II broth; catalog
number BBL 212322; Becton Dickinson, Franklin Lakes, NJ) with 25 g/ml G6P (Sigma-Aldrich), resulting
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in a bacterial density of 1  107 CFU/ml. The bacterial suspension was incubated at 37°C with shaking
(140 rpm) for 25 min, and 1 ml was added to tubes containing 19 ml of fosfomycin at different
concentrations proportional to the MIC for each strain in MH broth with 25 mg/liter G6P (Sigma-Aldrich),
resulting in a bacterial density of approximately 5  105 CFU/ml. Viable counts were determined at time
points of 0, 0.5, 1, 2, 4, and 24 h after the start of antimicrobial exposure using spot serial dilution (60).
Single NU14 colonies appearing on the MH agar plates used for determination of the number of CFU
(for each fosfomycin concentration, including a negative control, at time points of 0 h, 4 h, and 24 h) were
resuspended and tested for a change in the fosfomycin MIC by agar dilution, as described above. The
isolated subpopulations were further passaged five times on MH agar medium (Oxoid, Waltham, MA) to
evaluate the stability of the fosfomycin MIC.
PK studies. Three studies of the pharmacokinetics (PK) of fosfomycin in the bloodstream and urine
were performed in outbred female albino OF-1 mice (weight, 30 g; Charles River Laboratories,
Chatillon-sur-Chalaronne, France) given a single subcutaneous (s.c.) dose of 0.75, 7.5, and 30 mg
fosfomycin per mouse, respectively. Blood was sampled by periorbital cut-down, and urine was collected
directly in an Eppendorf tube by placing the tube over the orifice and gently tapping the mouse on the
abdomen. Samples were drawn at 15, 30, 60, 120, 180, and 240 min after dosing. Three mice were
sampled at each time point. Blood was sampled in EDTA-coated Eppendorf tubes (Eppendorf, Hamburg,
Germany), the tubes were centrifuged at 1,800  g, and plasma was transferred to fresh Eppendorf tubes
and stored at 80°C. Urine was also sampled in Eppendorf tubes and stored at 80°C. Fosfomycin
concentrations were measured by a bioassay using the fosfomycin-susceptible E. coli ATCC 25922 strain.
A bacterial suspension (106 CFU/ml) was floated on MH agar plates (Oxoid), and paper discs (Oxoid) were
placed on the inoculated agar. Twenty microliters of fosfomycin standards (1.1, 3.3, 11, 33, and 100
mg/liter) spiked in pooled mouse plasma or urine from untreated mice was pipetted onto each disc. The
same procedures were performed with triplicate samples from plasma and urine from treated mice. After
overnight incubation, the inhibition zone diameters were measured and the concentrations were
calculated from standard curves using regression analysis. For concentrations higher than 100 mg/liter,
samples were diluted in plasma or urine until measured values below the maximum standard were
obtained. The standard concentrations showed a day-to-day variation of 10%.
Calculation of dosing regimens. Doses for the in vivo activity study were designed to vary the TMIC
and AUC/MIC0 –72. Through interpolation and extrapolation of the PK data, the exponential equation
describing the concentration curve was estimated. Dose-dependent PK indices (AUC/MIC0 –72, TMIC,
Cmax/MIC) were computed on the basis of the total drug concentrations. TMIC (percent per 72 h) was
calculated as the percentage of time that the drug concentration was above the MIC for the test strain
(NU14; MIC, 1 mg/liter) during the treatment period (72 h); indices related to concentration dependence
(Cmax/MIC) were calculated on the basis of the highest concentrations observed experimentally 15 to 240
min after the s.c. dose (for the doses of 30 mg and 7.5 mg) or through interpolation and extrapolation
(for the other doses). Since the maximal drug concentrations in plasma were registered at the first
measurement time point (15 min after injection), leading to the assumption that the real peak in the
fosfomycin concentration might have occurred before the first measurement, we additionally used the
“TMIC (in hours) after the first dose” as a surrogate marker for Cmax/MIC after the single dose as an index
by assuming that the longer the TMIC (in hours) after the first dose is, the higher the Cmax/MIC is. As the
total number of doses administered within 72 h varied significantly (1 to 12 doses per 72 h; Table 2), the
TMIC (in hours) after the first dose did not show a linear relationship with the TMIC (percent per 72 h).
Indices considering both time and concentration (AUC/MIC0 –72) were calculated as the size of the
area under the concentration-time curve divided by the MIC using the trapezoidal rule (regular). All
calculations were performed in GraphPad Prism (version 7) software (GraphPad Software, San Diego, CA).
The relevant PK indices for the applied dosages are listed in Table 2.
PK/PD, virulence, and in vivo activity studies. The virulence of the strains was confirmed in vivo
in the murine UTI model before proceeding to the treatment studies, as previously described (43, 44).
Briefly, immunocompetent outbred albino female mice (OF-1; Charles Rivers Laboratories, Chatillon-sur-
Chalaronne, France) were used. Three days prior to inoculation, the drinking water was replaced with 5%
glucose solution (Sigma-Aldrich). On the inoculation day, mice were given ibuprofen (Nurofen Junior;
Novartis, Basel, Switzerland) orally and tiletamine-zolazepam (Zoletil; Virbac SA, Carros, France) plus
butorphanol tartrate (Torbugesic; Fort Dodge Laboratories, IA, USA) subcutaneously. The bladders of
anesthetized mice were inoculated with 50 l a bacterial suspension containing approximately 109
CFU/ml. Transurethral inoculation was performed with a sterilized plastic catheter (Becton Dickinson, NC,
USA), which was further retracted. Urine was collected from day 2 to control for the establishment of
infection. Mice were observed for any signs of pain or illness during the next 3 days. On day 5, urine was
collected from the mice by gently pressing on the abdomen. The mice were then euthanized by cervical
dislocation and the remaining urine was added to the tubes. Subsequently, the emptied bladder and
both kidneys were aseptically removed. The urine samples were processed on the same day by spotting
(20 ml) of a series of 10-fold dilutions in duplicate (spot dilution technique) on bromothymol blue agar
plates (Statens Serum Institut, Copenhagen, Denmark). The organs were homogenized in a Tissue Lyser
apparatus (Qiagen, Ballerup, Denmark); organ homogenizing was performed by adding 0.9% saline to
the organs until the total volume of 500 l for bladders and 100 l for two kidneys was reached. Tissue
homogenates were stored frozen and used to determine viable bacterial counts on the next day as
described above for urine. Colony counts on plates were performed after 18 to 24 h of incubation at 37°C
in ambient atmosphere.
The NU14 strain was used for performing the PK/PD study, where the effect of the calculated
fractioned doses was evaluated. Infection in the murine model was initiated as described above. Six to
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18 mice per group were used for investigation of each dose (43, 44). At 24 h postinoculation (day 2), after
the collection of urine, mice were treated subcutaneously with fosfomycin (total doses of 2.82 to 30 mg
per mouse for a treatment period of 72 h at a dosing frequency ranging from a single dose to dosing
q6h; Table 2) or saline on days 2 to 4. On day 5, the colony counts in the urine, bladders, and kidneys
were determined as described above.
To evaluate the in vivo activity of a selected dose on the basis of the results of the PK/PD study, the
effect of treatment against three isogenic strains of NU14 and clinical MDR E. coli strains with different
fosfomycin MICs was tested (Table 1). The in vivo activity studies were performed as described above. For
each strain, animal groups were treated with either 15 mg fosfomycin q36h per mouse (7 mice) or vehicle
(6 or 7 mice).
For the clinical isolates, bacterial populations that survived during the in vivo fosfomycin treatment were
collected. Two colonies from both the treatment and vehicle groups and, when possible, from the same
mouse were collected from plates on which urine was seeded on day 2 and from plates for the colony counts
for every site of infection (urine, bladder, and kidneys) on day 5. Further, the fosfomycin MICs for these
colonies were compared to the MICs for strains isolated from the same mouse on day 2. PCR was used to
confirm the presence of ESBL, plasmid-mediated AmpC, and carbapenemase genes as described before
(61–63). The fosfomycin MIC for the surviving strains was determined by agar dilution, as described above.
Statistical analysis. GraphPad Prism (version 7) software (GraphPad Software, San Diego, CA, USA)
was used for the PK/PD analysis. The relationship between the effect and PK/PD indices was analyzed
according to a sigmoidal Hill function (four-parameter dose-response curve). For each PK/PD index, the
data were fitted simultaneously for all distinct doses using nonlinear regression with the ordinary
least-squares (OLS) algorithm. Due to the high proportion of mice in all dose groups with reductions in
the number of CFU per milliliter below the LOD, we used the cumulative effect, measured in percent
(defined as the bactericidal effect), as the PD endpoint (64). This approach accounted for the high
proportion of cases with colony counts below the LOD and the 40% proportion of nonaffected/self-
recovered kidneys in the control group. For urine and kidneys, the bactericidal effect was defined as the
counts (number of CFU per milliliter) below the LOD, while for bladder counts (number of CFU per
milliliter), the bactericidal effect was defined as the proportion of counts (number of CFU per milliliter)
that were lower than that for the control group.
In the in vivo activity study with clinical strains, the median counts (number of CFU per milliliter) were
compared pairwise (between the treatment and vehicle-treated groups, separately for each strain) using
the Mann-Whitney test (two-tailed) with a significance level of a P value of 0.05 (GraphPad Prism
[version 7] software). For each strain, a separate control group treated with vehicle was used. We chose
not to perform the correction for multiple comparisons (65).
Ethical considerations. The animal experiments were carried out at the animal facility at the Statens
Serum Institute, Copenhagen, Denmark, and approved by the Danish Animal Experimentation Inspec-
torate (no. 2014-15-0201-00204).
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